PRESS-RELEASE ·Filed May 8, 2026

CYTK

Cytokinetics, Incorporated
BEARISH
Impact 6/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release: offering
Actionable Insight ▼ Bearish

The offering overhang may pressure CYTK shares in the short term as the 11.3 million new shares enter the market. Monitor for price stabilization and any updates on use of proceeds. Historically, similar-sized offerings for biotechs can lead to 5-10% declines within a week.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
CYTK ▲ +2.21% at T+60d
SHORT call ✗ call lost -2.21% · α vs SPY +2.63% · entry $76.91 → $78.61
Entry anchored
May 8, 10:50 AM ET
via exchange tick
T+1d
-3.06%
call +3.06% · α +3.29%
$74.56
settled 5mo ago
T+5d
+2.25%
call -2.25% · α -0.79%
$78.64
settled 5mo ago
T+20d
-7.06%
call +7.06% · α +7.08%
$71.48
settled 4mo ago
T+60d
+2.21%
call -2.21% · α +2.63%
$78.61
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Cytokinetics closed an underwritten public offering of 11.3 million shares at $71.00 per share, raising approximately $805 million in gross proceeds. The offering represents dilution of about 8.7% of the pre-offering market capitalization, which may pressure the stock in the near term as the additional shares enter the market.

Key Financial Metrics

Deal Value
$805.0M

Key Facts

  • Offering of 11,338,028 shares at $71.00 per share
  • Gross proceeds of approximately $805 million
  • Full exercise of underwriters' option to purchase additional shares
  • Closing of offering announced on May 08, 2026

Financial Impact

Gross proceeds of $805 million, representing dilution of approximately 8.7% of pre-offering market capitalization

dilutioncash

Risk Factors

  • Dilutive effect of 8.7% increase in share count
  • Potential short-term selling pressure from offering participants
  • Uncertainty about use of proceeds

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (27 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291210
32 reports for CYTK
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+20▲ +10.38%Mar 31, 2026
Filters
Rows
Reports for CYTK — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
BEARISH ★ 5/10
$69.31 $67.59▲ +2.48%▲ +4.59%$65.60 (+5.35%)
Sep 11, 2026
20d ago
Insider Cluster
NEUTRAL ★ 2/10
$72.45 $67.56▼ −6.75%▼ −6.86%$65.60 (−9.45%)
Sep 1, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 31, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$71.40 $74.11▲ +3.80%▲ +3.71%$65.60 (−8.12%)
Aug 29, 2026
4w ago
Press Release
BULLISH ★ 7/10
$70.91 $75.35▲ +6.26%▲ +6.40%$65.60 (−7.49%)
Aug 28, 2026
5w ago
8-K
BULLISH ★ 7/10
$72.09 $72.72▲ +0.87%▲ +0.76%$65.60 (−9.00%)
Jul 30, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.42 $81.37▲ +1.18%▼ −2.44%$65.60 (−18.43%)
Jul 27, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$80.62 $77.13▼ −4.33%▼ −5.40%$65.60 (−18.63%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$80.74 $80.42▼ −0.40%▼ −0.77%$65.60 (−18.75%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.93 $79.11▼ −3.44%▼ −2.15%$65.60 (−19.93%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 8, 2026